Objective: COVID 19 is having a devastating effect on mankind’s life. Individuals with COVID-19 will experience high levels of stress, depression, anxiety, and low quality of life. The goals the of present study were to investigate the effect of brief crisis intervention package on stress, depression, anxiety, and quality of life in patient with COVID-19. Method: In this randomized controlled clinical trial, 30 patients were randomly selected and divided into control and experimental groups. The experimental group was examined in four 60-minute sessions for one month. During this period, the control group received only routine treatment and therapy. Before and after the intervention, DASS21, the Symptom Checklist (SCL-25), and WHO-QOL were used to measure and record patient mental health and quality of life. Finally, data were analyzed using SPSS 24 software. Results: The average mental health score was assessed with WHO-QOL, DASS21, and SCL-25 before intervention and was not statistically significant (P = > 0.05), and the mean score of stress, anxiety, depression, WHO-QOL, SCL-25 after intervention was statistically significant (P < 0.001). Therefore, results showed the brief crisis intervention package was effective in improving the quality of life (P < 0.05) and mental illnesses (P < 0.05) in patients with COVID-19. Conclusion: The brief crisis intervention package can reduce the negative effect of patients with COVID-19. Therefore, this intervention can be used as a beneficial treatment to improve mental disorder symptoms and to improve the condition of people who suffer from COVID-19.

IRCT201201247202N2.

No abstract

Background: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. Various factors can delay the timely diagnosis of adult ADHD. The brown attention deficit disorder scales (BADDS) is a consistent measure of attention deficit disorder (ADD) across the life span. Objectives: This article aims to examine the reliability and validity of a Persian version of the BADDS. Methods: A total of 100 participants were enrolled in this descriptive study by convenience sampling. Cases were recruited from the adult ADHD outpatient clinic of Roozbeh psychiatry hospital in 2019. Controls were from the caregivers of patients presenting to Roozbeh general psychiatry outpatient clinic. The conners adult ADHD rating scale was used to measure concurrent validity. Results: Cronbach's Alpha was 0.979 for the test ranging from 0.888 to 0.942 for the clusters. Also, the intra-class coefficient (0.977) confirmed strong internal stability. For the cut-off point of 55, the sensitivity was 96%, and the specificity was 74%. Our study demonstrated a significant relationship between the C scale and the D scale of the Conner's test and the total score of the BADDS questionnaire (r = 0.61 and r = 0.64, respectively), verifying the concurrent validity of the instrument. Construct validity was evaluated by the t-test. All five clusters' total and subtotal scores were significantly higher in the patients compared to the controls. Conclusions: The Persian version of BADDS is reliable and valid and can be used in clinical settings.

Introduction: Alexander disease is a heterogenous group of diseases with various manifestations based on age of disease onset. This rare leukodystrophy syndrome with mutations in GFAP Gene could present with developmental delay and seizure in infantile form to ataxia and bulbar palsy in adulthood. However psychiatric symptoms are not well-defined and usually evaluate after disease diagnosis not before disease investigations. Case report: Our patient is a fifty-two-year-old Iranian woman with history of depression from about 17 years ago, suicidal attempt two years ago and ingestion a large amount of opium with the intention of suicide 2 months ago who was presented with disorientation and probably delirious state in the last interview. Eventually in comprehensive investigations, white matter hyperintensity and leukodystrophy was diagnosed and ultimately to determine the cause of these changes with gene study, whole and Exon deletion of GFAP Gene Late Onset Alexander disease was determined. Conclusion: Neurological-onset manifestation of Alexander disease specifically late onset form is the most common clinical picture of disease and was seen in about 90% of patients but psychiatric symptoms are not well-known and psychiatric- onset disease was not described yet. On the other hand, various Gene Mutation were described in Late Onset Alexander Disease, however large whole Exon deletion which was revealed in our patient is a novel mutation and significantly need to be declared. Here authors describe a late onset Alexander disease with psychiatric onset symptoms and novel large Exon deletion in GFAP Gene.